<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00848185</url>
  </required_header>
  <id_info>
    <org_study_id>IVIMAD-MC-10-2008-01</org_study_id>
    <nct_id>NCT00848185</nct_id>
  </id_info>
  <brief_title>Differential Regulation of VEGF, Cadherin, Angiopietin 2 by Trigger Oocyte Maturation With GnRHa vs hCG in Donors</brief_title>
  <official_title>Differential Regulation of VEGF, Cadherin and Angiopietin 2 by Trigger Oocyte Maturation With GnRHa vs hCG in Donors: Try to Explain the Lower OHSS Incidence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IVI Madrid</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IVI Madrid</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Introduction OHSS still remains a complication of assisted reproduction treatments. hCG
      administration to trigger final oocyte maturation will release vascular mediators, being VEGF
      and other proteins such as VE-Cadherin or Angiopoietin- 2. It has been shown that replacing
      hCG by GnRH agonists will induce a very short endogenous LH peak, potent enough to induce
      final oocyte maturation but no OHSS will develop. The investigators examined VEGF,
      VE-Cadherin and Angiopoietin-2 modulation by hCG as well as GnRH agonists in oocyte donors
      undergoing controlled ovarian stimulation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Material and Methods Between June and December of 2008 we evaluated 90 egg donors. They
      underwent COH with 150 IU rFSH as starting dose, we separated them in 3 groups (n:30 each):
      Groups 1 and 2 received a 0.25mg daily dose of GnRH antagonist when a follicle 14mm in
      diameter was observed. hCG 250g was given to group 1 while group 2 received triptorelin 0.2mg
      when leading two follicles were 17mm. Group 3 was stimulated with standard long protocol, hCG
      was given following similar criteria.

      Blood was collected the day of hCG/aGnRH administration as well as the day of egg retrieval,
      and follicular fluid from the first two mature follicles was also frozen. We collected
      granulosa cells (GC) of 10 patients of each group as well Levels of VEGF, sVE-Cadherin an
      Angiopietin 2 were determined by ELISA in serum and in follicular fluid.

      Results were analyzed via ANOVA.Data are expressed as meanÂ± SEM. A significant difference was
      defined as p&lt; 0.05.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>VEGF Protein and mRNA Levels</measure>
    <time_frame>1 year</time_frame>
    <description>VEGF concentration in follicular fluid and VEGF mRNA expression in granulosa cells from patients who received either GnRH agonist instead of hCG</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">96</enrollment>
  <condition>Vascular Endothelial Growth Factor Overexpression</condition>
  <arm_group>
    <arm_group_label>Antagonist-hCG for triggering</arm_group_label>
    <description>Protocol with antagonist and hCG to trigger oocyte maturation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antagonist-aGnRH for triggering</arm_group_label>
    <description>Protocol with antagonist and 0,2 mg triptorelin to trigger oocyte maturation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Long protocol-hCG for triggering</arm_group_label>
    <description>Long Protocol and hCG to trigger oocyte maturation</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      follicular fluid
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        oocyte Donors
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Donors

        Exclusion Criteria:

          -  Important diseases
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>34 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2009</study_first_submitted>
  <study_first_submitted_qc>February 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2009</study_first_posted>
  <results_first_submitted>February 25, 2016</results_first_submitted>
  <results_first_submitted_qc>March 5, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 17, 2017</results_first_posted>
  <last_update_submitted>March 5, 2017</last_update_submitted>
  <last_update_submitted_qc>March 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IVI Madrid</investigator_affiliation>
    <investigator_full_name>Juan A Garcia-Velasco</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>VEGF</keyword>
  <keyword>Trigger</keyword>
  <keyword>OHSS</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Antagonist Trigger With aGnRH</title>
          <description>Protocol with antagonist and 0,2 mg triptorelin to trigger oocyte maturation</description>
        </group>
        <group group_id="P2">
          <title>Antagonist Trigger With hCG</title>
          <description>Protocol with antagonist and hCG to trigger oocyte maturation</description>
        </group>
        <group group_id="P3">
          <title>Long Protocol hCG</title>
          <description>Long Protocol with hCG to trigger oocyte maturation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Age between 18 and 35 years and previous pregnancy
Regular menstrual cycles (between 25 and 35 days)
Normal karyotype
Body massindex between 18 and 25 kg/m2
Negative serology for VHB, VHC and HIV
Normal cervical cytology in the past year, and a vaginal ultrasound without evidence of any pathologic conditions</population>
      <group_list>
        <group group_id="B1">
          <title>Antagonist-hCG to Trigger</title>
          <description>Protocol with antagonist and hCG to trigger oocyte maturation</description>
        </group>
        <group group_id="B2">
          <title>Antagonist-aGnRH to Trigger</title>
          <description>Protocol with antagonist and 0.2 mg triptorelin to trigger oocyte maturation</description>
        </group>
        <group group_id="B3">
          <title>Long Protocol-hCG</title>
          <description>Long Protocol and hCG to trigger oocyte maturation</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="32"/>
            <count group_id="B3" value="32"/>
            <count group_id="B4" value="96"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="96"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.2" spread="3.5"/>
                    <measurement group_id="B2" value="23.7" spread="3.9"/>
                    <measurement group_id="B3" value="24.5" spread="3.7"/>
                    <measurement group_id="B4" value="25.1" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="96"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>The donors were recruit for the clinic</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>VEGF Protein and mRNA Levels</title>
        <description>VEGF concentration in follicular fluid and VEGF mRNA expression in granulosa cells from patients who received either GnRH agonist instead of hCG</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Antagonist-hCG Levels of VEGF</title>
            <description>Levels of VEGF in folicular fluid of patients with antagonist protocol anf hCG for triggering</description>
          </group>
          <group group_id="O2">
            <title>Antagonist-aGnRH Levels of VEGF</title>
            <description>Levels of VEGF in folicular fluid of patients with antagonist protocol and aGnRH for triggering</description>
          </group>
          <group group_id="O3">
            <title>Long Protocol- hCG</title>
            <description>Levels of VEGF in folicular fluid of patients with long protocol anf hCG for triggering</description>
          </group>
        </group_list>
        <measure>
          <title>VEGF Protein and mRNA Levels</title>
          <description>VEGF concentration in follicular fluid and VEGF mRNA expression in granulosa cells from patients who received either GnRH agonist instead of hCG</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1395" spread="284"/>
                    <measurement group_id="O2" value="1069" spread="354"/>
                    <measurement group_id="O3" value="1666" spread="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>ANOVA for three groups</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>GnRH Antagonist - hCG Trigger</title>
          <description>GnRH antagonist protocol and hCG trigger</description>
        </group>
        <group group_id="E2">
          <title>GnRH Antagonist Triptorelin Trigger</title>
          <description>GnRH antagonist protocol and triptorelin trigger</description>
        </group>
        <group group_id="E3">
          <title>Long Protocol - hCG Trigger</title>
          <description>Long protocol and hCG trigger as control</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dra Cerrillo</name_or_title>
      <organization>IVI Madrid</organization>
      <phone>911802900</phone>
      <email>maria.cerrillo@ivi.es</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

